Corinne Johnson
Stock Analyst at Goldman Sachs
(4.45)
# 1,170
Out of 4,690 analysts
245
Total ratings
54.2%
Success rate
14.2%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintained: Hold | $33 → $37 | $39.21 | -5.64% | 23 | Jul 16, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $34 | $19.54 | +74.00% | 8 | Jul 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | $20 → $23 | $34.74 | -33.79% | 19 | Jun 18, 2026 | |
| HALO Halozyme Therapeutics | Maintained: Sell | $56 → $57 | $105.35 | -45.89% | 18 | Jun 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $158 → $159 | $107.17 | +48.36% | 31 | Jun 14, 2026 | |
| TGTX TG Therapeutics | Maintained: Hold | $41 | $53.93 | -23.98% | 21 | Jun 3, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Hold | $35 → $36 | $40.11 | -10.25% | 11 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $154.06 | +38.26% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $13.24 | +13.29% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Maintained: Buy | $27 → $25 | $15.41 | +62.23% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2.5 | $3.11 | -19.61% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $28 → $32 | $41.20 | -22.33% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $38 → $41 | $34.71 | +18.12% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $102 → $101 | $47.37 | +113.22% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.51 | -33.77% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $82 | $74.34 | +10.30% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $63.00 | -49.25% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $30.17 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.85 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $2.34 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $7.94 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.1814 | n/a | 14 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.01 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $0.985 | n/a | 1 | Sep 14, 2021 |
Harmony Biosciences Holdings
Jul 16, 2026
Maintained: Hold
Price Target: $33 → $37
Current: $39.21
Upside: -5.64%
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $34
Current: $19.54
Upside: +74.00%
Amylyx Pharmaceuticals
Jun 18, 2026
Maintained: Buy
Price Target: $20 → $23
Current: $34.74
Upside: -33.79%
Halozyme Therapeutics
Jun 14, 2026
Maintained: Sell
Price Target: $56 → $57
Current: $105.35
Upside: -45.89%
Rhythm Pharmaceuticals
Jun 14, 2026
Maintained: Buy
Price Target: $158 → $159
Current: $107.17
Upside: +48.36%
TG Therapeutics
Jun 3, 2026
Maintained: Hold
Price Target: $41
Current: $53.93
Upside: -23.98%
IDEAYA Biosciences
Jun 3, 2026
Maintained: Hold
Price Target: $35 → $36
Current: $40.11
Upside: -10.25%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $154.06
Upside: +38.26%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $13.24
Upside: +13.29%
Biohaven
May 28, 2026
Maintained: Buy
Price Target: $27 → $25
Current: $15.41
Upside: +62.23%
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $3.11
Upside: -19.61%
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $41.20
Upside: -22.33%
Apr 15, 2026
Maintained: Buy
Price Target: $38 → $41
Current: $34.71
Upside: +18.12%
Mar 16, 2026
Maintained: Buy
Price Target: $102 → $101
Current: $47.37
Upside: +113.22%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.51
Upside: -33.77%
Jan 12, 2026
Maintained: Buy
Price Target: $56 → $82
Current: $74.34
Upside: +10.30%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $63.00
Upside: -49.25%
Jul 18, 2025
Maintained: Buy
Price Target: n/a
Current: $30.17
Upside: n/a
Jul 31, 2024
Maintained: Buy
Price Target: n/a
Current: $3.85
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $2.34
Upside: n/a
Jun 18, 2024
Maintained: Hold
Price Target: n/a
Current: $7.94
Upside: n/a
Nov 14, 2023
Reiterated: Hold
Price Target: n/a
Current: $0.1814
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $6.01
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $0.985
Upside: n/a